What is the current market price of dacomitinib (dacomitinib)? Details per box

Dacomitinib (Dacomitinib) is a second-generation EGFR targeted inhibitor, mainly used to treat patients with advanced non-small cell lung cancer (NSCLC), especially cases with positive EGFR sensitive mutations. At present, the original drug of dacomitinib has been successfully launched in China and has been included in the national medical insurance reimbursement project, reducing the financial burden of medication for patients.

In the domestic market, the original drug specification of dacomitinib is 15 mg After medical insurance reimbursement, the actual price paid by the patient drops significantly and can generally be controlled at around 1,300 yuan. The specific reimbursement ratio will vary due to regional differences and medical insurance policies. Patients can consult the local medical insurance department for detailed information.

In the European market, the original drug specifications of dacomitinib are 45mg This is mainly due to differences in the medical insurance systems and drug pricing mechanisms of different countries, and the prices of drugs with larger dosages are naturally higher. For patients with limited financial resources, drug prices in Europe and other regions can become a burden.

In addition, dacomitinib is also available as a generic drug in Laos, and the price is relatively affordable. The price of the dacomitinib generic drug produced by Lucius Pharmaceuticals in Laos is about 1,000 yuan, with obvious price advantages. Although generic drugs are low in price, patients should pay attention to the quality and source of the drug when choosing to ensure the safety and efficacy of the drug. Generally speaking, the price of dacomitinib varies greatly in different markets, and patients should choose the appropriate drug purchase channel based on their actual situation.

Reference materials:https://www.drugs.com